Clinical Trial Update: Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating imipenem+cilastatin/relebactam versus colistimethate sodium+imipenem+cilastatin in imipenem-resistant bacterial infections; results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Drugs mentioned

• Colistimethate Sodium+Imipenem+Cilastatin (colistimethate sodium + imipenem-cilastatin)
• Imipenem/Cilastatin/Relebactam (imipenem/cilastatin/relebactam)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bacterial Infections | Phase 3 | Status: COMPLETED | Results posted: 2018-10-19